Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (11063)	3/6/2017 10:23:47 PM
From: tuck	Read Replies (1) \| Respond to of 12215

PIRS P1 against hepcidin was a single ascending dose trial. No repeat dosing in humans yet that I'm aware of. The ongoing trial is also single dose. They are looking for anti-PRS-080 antibodies at day 28, same as the completed trial. The summation of P1 data has a hard to format table, so linking, rather than copying: A Phase I Study Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of the Hepcidin Antagonist PRS-080#022. Results from a Randomized, Placebo Controlled, Double-Blind Study Following Single Administration to Healthy Subjects Cheers, Tuck

To: scaram(o)uche who wrote (11063)	3/7/2017 9:44:22 AM
From: Biotech Jim	Respond to of 12215

<I don't expect anyone to go out and dig up answers, particularly you, Jim. Just throwing stuff out.> Nothing wrong with that request, Rick. If it is over my head, or if I just don't feel like it, I just will not respond! Is the cyno macaque a good model for immune responses and speculatively in vivo anti-calin antibody generation? I suspect they have repeat high dose tox studies, as they commented on other aspects of doing in macaques in preclinical studies. I do not know about half lives. PIRS, can you send me the summary of all GMP tox studies done with anti-calins to date?